New trends in the treatment of androgenetic alopecia

Szymon Leonik; Michał Smoczok; Beata Bergler-Czop

doi:10.5114/dr.2024.146624

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

4/2024
vol. 111

Send email

Copy url:

abstract:

Review article

New trends in the treatment of androgenetic alopecia

Szymon Leonik

¹

,

Michał Smoczok

²

,

Beata Bergler-Czop

¹

Department of Dermatology, Medical University of Silesia, Katowice, Poland
Department of Plastic, Reconstructive and Aesthetic Surgery, Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland

Dermatol Rev/Przegl Dermatol 2024, 111, 273-279

DOI: https://doi.org/10.5114/dr.2024.146624

Online publish date: 2025/01/17

View full text Get citation

PlumX metrics:

Androgenetic alopecia is the most common form of non-cicatricial hair loss, affecting a significant proportion of the population, particularly men. Due to increasing societal demands for a flawless appearance, there is an increase in pressure on physicians and specialists to provide effective and safe treatment for patients suffering from androgenic alopecia. However, treatments with proven efficacy approved by recognised organisations and associations are limited, and research is ongoing to discover new drugs, redesign existing ones and establish therapy algorithms. This publication reviews the use of minoxidil, 5a-reductase inhibitors (applied orally, topically and by injection), tretinoin, botulinum toxin, microRNA, and osteopontin as treatment options for androgenetic alopecia in men.

keywords:

New trends in the treatment of androgenetic alopecia

Szymon Leonik 1 , Michał Smoczok 2 , Beata Bergler-Czop 1

microRNA, botulinum toxin, minoxidil, androgenetic alopecia, 5a-reductase inhibitor

Szymon Leonik

¹

,

Michał Smoczok

²

,

Beata Bergler-Czop

¹